U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H22N2O
Molecular Weight 246.3485
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MILNACIPRAN

SMILES

CCN(CC)C(=O)[C@@]1(C[C@]1([H])CN)c2ccccc2

InChI

InChIKey=GJJFMKBJSRMPLA-HIFRSBDPSA-N
InChI=1S/C15H22N2O/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12/h5-9,13H,3-4,10-11,16H2,1-2H3/t13-,15+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022256s013lbl.pdf

Milnacipran is the only marketed serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) reported to have greater relative potency at NET than SERT in vitro and is the first SNRI to report equal occupancy of both transporters at clinical doses. Milnacipran is a racemic mixture of the 1S, 2R (F2695/levomilnacipran) and 1R, 2S (F2696/dextromilnacipran) enantiomers. Savella® (Milnacipran) is indicated for the management of fibromyalgia.

Originator

Curator's Comment:: Milnacipran was synthesised as a racemic mixture at the PIERRE FABRE MEDICAMENT Research Centre (Castres, France).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
290.0 nM [Ki]
16.9 nM [Ki]
139.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SAVELLA

Approved Use

Savella is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients [see Use in Specific Populations (8.4)

Launch Date

1.2318912E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
132 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
150 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1316.9 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
6 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
87%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
87%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MILNACIPRAN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.593
unhealthy, 48.6
n = 181
Health Status: unhealthy
Condition: Fibromyalgia
Age Group: 48.6
Sex: M+F
Population Size: 181
Sources: Page: p.593
Disc. AE: Nausea, Blood pressure increased...
AEs leading to
discontinuation/dose reduction:
Nausea (2.4%)
Blood pressure increased (1.4%)
Heart rate increased (1%)
Sources: Page: p.593
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Disc. AE: Suicidal ideation, Serotonin syndrome...
AEs leading to
discontinuation/dose reduction:
Suicidal ideation
Serotonin syndrome
Neuroleptic malignant syndrome
Blood pressure increased
Heart rate increased
Seizures
Hepatotoxicity
ALT increased (mild)
Aspartate aminotransferase increase (mild)
Hepatitis fulminant (rare)
Bleeding
Sources: Page: p.1
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Disc. AE: Nausea, Palpitations...
AEs leading to
discontinuation/dose reduction:
Nausea (6%)
Palpitations (3%)
Headache (2%)
Constipation (1%)
Heart rate increased (1%)
Hyperhidrosis (1%)
Vomiting (1%)
Dizziness (1%)
Sources: Page: p.11
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.5
Disc. AE: Suicidal ideation...
AEs leading to
discontinuation/dose reduction:
Suicidal ideation (1.3%)
Sources: Page: p.5
AEs

AEs

AESignificanceDosePopulation
Heart rate increased 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.593
unhealthy, 48.6
n = 181
Health Status: unhealthy
Condition: Fibromyalgia
Age Group: 48.6
Sex: M+F
Population Size: 181
Sources: Page: p.593
Blood pressure increased 1.4%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.593
unhealthy, 48.6
n = 181
Health Status: unhealthy
Condition: Fibromyalgia
Age Group: 48.6
Sex: M+F
Population Size: 181
Sources: Page: p.593
Nausea 2.4%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.593
unhealthy, 48.6
n = 181
Health Status: unhealthy
Condition: Fibromyalgia
Age Group: 48.6
Sex: M+F
Population Size: 181
Sources: Page: p.593
Bleeding Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Blood pressure increased Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Heart rate increased Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Hepatotoxicity Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Neuroleptic malignant syndrome Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Seizures Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Serotonin syndrome Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Suicidal ideation Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
ALT increased mild
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Aspartate aminotransferase increase mild
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Hepatitis fulminant rare
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.1
Constipation 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Dizziness 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Heart rate increased 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Hyperhidrosis 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Vomiting 1%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Headache 2%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Palpitations 3%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Nausea 6%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.11
Suicidal ideation 1.3%
Disc. AE
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Fibromyalgia
Sources: Page: p.5
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no (co-administration study)
Comment: no changes in PK of warfarin or milnacipran were observed
Page: 55.0
no
unlikely (co-administration study)
Comment: when coadministered with carbamazepine, exposure (Cmax and AUC) to milnacipran decreased by 18% and 19%, respectively;
Page: 55.0
no
unlikely (co-administration study)
Comment: At steady state, Cmax and AUC for milnacipran increased by only 10% and 20% when coadministered with levomepromazine; no changes in PK of warfarin or milnacipran were observed
Page: 55.0
no
unlikely (co-administration study)
Comment: when coadministered with carbamazepine, exposure (Cmax and AUC) to milnacipran decreased by 18% and 19%, respectively;
Page: 55.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Which bioequivalence study for a racemic drug? Application to milnacipran.
1998 Apr-Jun
Elevation of blood pressure induced by high-dose milnacipran.
2002 Dec
Remarkable effect of milnacipran in the treatment of Japanese major depressive patients.
2002 Jun
Clinical utility of milnacipran in comparison with other antidepressants.
2002 Jun
Japanese experience with dual-action antidepressants.
2002 Jun
Pharmacology and pharmacokinetics of milnacipran.
2002 Jun
Optimizing antidepressant treatment: efficacy and tolerability.
2002 Jun
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
2002 Nov 15
Silent thyroiditis associated with short-term lithium therapy.
2002 Nov-Dec
Mechanism of action of antidepressants.
2002 Summer
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].
2003
Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury.
2003 Aug
Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
2003 Dec
Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
2003 Dec
The clinical use of milnacipran for depression.
2003 Feb
Dual monoamine modulation for improved treatment of major depressive disorder.
2003 Feb
New hope in the treatment of painful symptoms in depression.
2003 Jan
Parkinsonism associated with a serotonin and noradrenaline reuptake inhibitor, milnacipran.
2003 Jan
Functional expression of the norepinephrine transporter in cultured rat astrocytes.
2003 Jan
Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
2003 Jun
Modulation of the human glucocorticoid receptor function by antidepressive compounds.
2003 May 22
Milnacipran for the treatment of chronic pain.
2003 Oct
Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports.
2003 Sep-Oct
Effects of milnacipran on the inhibitory postsynaptic potential in neurons of the rat locus coeruleus.
2004
Milnacipran treatment of a terminally ill cancer patient with major depressive disorder.
2004 Aug
Differential effects of fluvoxamine, paroxetine and milnacipran for depression, especially with regard to age.
2004 Aug
[Review of antidepressants from the TCAs to the third generation drugs].
2004 Dec
Acute effect of milnacipran on the relationship between the locus coeruleus noradrenergic and dorsal raphe serotonergic neuronal transmitters.
2004 Dec
Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.
2004 Dec
A comparative study of milnacipran and paroxetine in outpatients with major depression.
2004 Dec
Ejaculation after defecation without orgasm induced by milnacipran.
2004 Fall
[Acute hepatitis associated with milnacipran treatment].
2004 Feb
Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment.
2004 Feb
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
2004 Feb 1
Reboxetine: a norepinephrine selective reuptake pump inhibitor.
2004 Jan
Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection.
2004 Jul 5
Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
2004 Mar
Augmentation of milnacipran by risperidone in treatment for major depression.
2004 Mar
Nociceptin/orphanin FQ, hedonic state and the response to abused drugs.
2004 Oct
Serotonin and noradrenaline reuptake inhibitors in animal models of pain.
2004 Oct
A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia.
2004 Oct
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
2004 Sep 13
Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
2005 Feb
[Effects of milnacipran on neuronal excitability and synaptic transmission in neurons of the rat locus coeruleus].
2005 Jan
Lithium augmentation in milnacipran-refractory depression for the prevention of relapse following electroconvulsive therapy.
2005 Jan-Feb
Anxiolytic-like effect of milnacipran in the four-plate test in mice: mechanism of action.
2005 Jul
The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain.
2005 May
The effect of milnacipran (serotonin noradrenaline reuptake inhibitor) on memory in Korsakoff's syndrome after encephalitis.
2005 May-Jun
Peripheral circulatory disturbance induced by milnacipran.
2005 Winter
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.
2013 Jul
Patents

Sample Use Guides

Milnacipran and the L enantiomer were effective in reducing immobility in the forced swim test in rodents (EC50 ~10 mg/kg PO and ~3 mg/kg PO, respectively) compared with D enantiomer (EC50 ≥100 mg/kg PO).
Route of Administration: Oral
Dextromilnacipran inhibits norepinephrine and serotonin reuptake in rat hypothalamic synaptosomes with IC50 values of 750 and 600 nM, respectively
Name Type Language
MILNACIPRAN
EMA EPAR   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
MILNACIPRAN [MI]
Common Name English
MILNACIPRAN [WHO-DD]
Common Name English
MILNACIPRAN [INN]
Common Name English
(1RS,2SR)-2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE
Systematic Name English
MILNACIPRAN [VANDF]
Common Name English
IMPULSOR
Brand Name English
MILNACIPRAN [EMA EPAR]
Common Name English
MILNACIPRAN PIERRE FABRE MEDICAMENT
Brand Name English
CYCLOPROPANECARBOXAMIDE, 2-(AMINOMETHYL)-N,N-DIETHYL-1-PHENYL-, (1R,2S)-REL-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29747
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
WHO-VATC QN06AX17
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
EMA ASSESSMENT REPORTS IMPULSOR (REFUSED, FIBROMYALGIA)
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
NDF-RT N0000000109
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
NCI_THESAURUS C265
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
NDF-RT N0000175749
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
NDF-RT N0000000102
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
LIVERTOX 639
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
EMA ASSESSMENT REPORTS MILNACIPRAN PIERRE FABRE MEDICAMENT (REFUSED: FIBROMYALGIA)
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
WHO-ATC N06AX17
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
EMA ASSESSMENT REPORTS IMPULSOR (REFUSED: FIBROMYALGIA)
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
Code System Code Type Description
MESH
C048107
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
RXCUI
588250
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
MILNACIPRAN
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
NCI_THESAURUS
C78021
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
IUPHAR
7436
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
ChEMBL
CHEMBL259209
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
FDA UNII
G56VK1HF36
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
EPA CompTox
92623-85-3
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
MERCK INDEX
M7545
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY Merck Index
LACTMED
Milnacipran
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
DRUG BANK
DB04896
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
INN
5701
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
DRUG CENTRAL
1808
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
CAS
92623-85-3
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY
EVMPD
SUB08965MIG
Created by admin on Sat Jun 26 12:44:14 UTC 2021 , Edited by admin on Sat Jun 26 12:44:14 UTC 2021
PRIMARY